Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 48Recruiting 15Active not recruiting 14Terminated 9Unknown 7Withdrawn 3Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 2Dermatologic 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Melanoma 23Stomach Neoplasms 8Neoplasms 7Carcinoma, Renal Cell 6Carcinoma, Hepatocellular 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Hodgkin Disease 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Uveal Melanoma 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Carcinoma 2Brain Neoplasms 2

Interventions

Exercise 18Drug Therapy 17pembrolizumab 12Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Dexamethasone 9Paclitaxel 8Standard of Care 7Oxaliplatin 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Control Groups 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Nivolumab × Clear all
NCT05150236 2023-12-15

ANZUP2001

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
93 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

National Health Research Institutes, Taiwan

Phase 1 Unknown
12 enrolled
Tumor-Agnostic

Neoplasms

NCT05175235 2023-03-03

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

National University Hospital, Singapore

Phase 1/2 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

Ardigen

Unknown
130 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

Ardigen

Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04169867 2019-11-20

Polish Microbiome Map

Ardigen

Unknown
1,160 enrolled
Dermatologic

Melanoma, Neoplasms

NCT03792724 2019-01-03

INTRUST

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2 Unknown
32 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡